Khalid Islam

Adenium Biotech ApS develops and commercializes novel antibiotics for the treatment of multi drug resistant bacterial infections. It focuses on treatment of nosocomial infections, in particular complicated urinary tract infections and hospital or ventilator acquired pneumonia caused by multi drug resistant Gram-negative bacteria. The company offers Arenicin, an anti-microbial peptide against gram-negative pathogens for pneumonia, urinary tract infection, and acinetobacter baumanii. Adenium Biotech was founded by Peter Nordkild on August 24, 2011 and is headquartered in Copenhagen, Denmark.

Part of Sanofi, Hoechst Marion Roussel Group designs molecule inhibitors. The company is based in Frankfurt, Germany.

Sirius Healthcare Partners GmbH provides independent advice to small and mid-cap healthcare companies, venture capital firms, institutional and private investors. The firm's services include strategic advisory, mergers and acquisition and financing advisory. It serves in the area of biotechnology, medical technology and diagnostics, platform technologies and healthcare markets. The company was founded by Subhasis Roy, Khalid Islam, Ernesto Mancosu, Werner Tschollar, Andreas Vogler and Mikael von Euw and is headquartered in Zurich, Switzerland.

Kurma Biofund seeks investment opportunities in life science and biotechnology companies located in Europe. The investments are done in cooperation with medical institutes and universities such as Institut Pasteur and Institut Curie. Its investment size ranges between €0.10 and €6 million.

OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.

AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy.

Prev AbR LLC develops biologic and beta-lactamase compounds. The private company is based in Bethesda, MD. The company was founded by Khalid Islam.

Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain.

Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.

GT Gain Therapeutics SA operates as a preclinical stage biotech firm developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx technology. Its projects include Beta-galactosidase GLB1 gene and Glucosylceramidase GBA gene. The company was founded by Lorenzo Leoni and is headquartered in Lugano, Switzerland.

Elion Oncology, Inc. engages in the provision of pharmaceutical services. The company was founded in 2016 and is headquartered in Bethesda, MD.